Lifecare ASA

LIFE Strategic investment in RemoveAid AS

Bergen, Norway, 26th April 2024: Lifecare AS (LIFE), a clinical stage medical

sensor company developing the next generation Continuous Glucose Monitor

(CGM), intend to invest NOK 2 million and become the majority shareholder in

RemovAid AS, a medical technology company based in Oslo, Norway.

RemovAid is an ISO 13485 certified company who specializes in the development,

manufacture and distribution of medical devices which remove subdermal

implants. RemovAid has developed and patented an CE certified a class IIa

medical device for gentle and efficient removal single-rod contraceptive

implants.

About us

Lifecare AS is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, Lifecare AS, [email protected], +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs,

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR Article 19 no. 3. The information was submitted for publication

at 2024-04-26 13:29 CEST.

AI Terminal